Search

Depemokimab

[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients

Tipifarnib

It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

Gimeracil

It functions by reversibly and selectively blocking the enzyme dihydropyrimidine dehydrogenase (DPD), which is involved in the degradation of 5-FU [A31408].

Cenobamate

[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA_A and inhibits voltage gated sodium channels. … [L10653] Cenobamate was granted FDA approval on 21 November 2019.[L10653]

Naldemedine

It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.

Dicoumarol

In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.

Azelaic acid

It is also produced by _Malassezia furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human skin. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.

Sodium phosphate, monobasic, unspecified form